FORMULATION AND DEVELOPMENT OF KETOROLAC TROMETHAMINE OPHTHALMIC SOLUTION

An acetic acid derivative ketorolac tromethmine has found its applicability in both gram positive and gram negative bacterial ocular infection and used commonly associated with multiple doses. Ophthalmic medication stored in multiple dose containers is required by the U.S. Food and Drug Administration to contain a preservative so that patients are provided with microbe free medication. Benzalkonium chloride in concentrations from 0.1% to 0.0001% induced dose-dependent growth arrest and conjunctiva epithelial cell death, either delayed or immediately after administration. In such case, a preservative Benzalkonium chloride must be used within reasonable bound. Benzalkonium chloride can provide more help than harm. Hence the present study focusing on to  formulate a formulation for ketorolac tromethmine (0.5%) ophthalmic solution using different concentration of Benzalkonium chloride as preservative. Keywords: Ketorolac tromethamine, Ophthalmic, benzalkonium chloride, conjunctiv